It’s been a year since the gene-editing treatment Casgevy was approved for sickle cell disease and a related blood disorder.

Rotten tomatoes no more: growing sweeter tomatoes is possible by editing just two of the fruit’s genes. Deleting the genes ...

Today’s mass-produced tomatoes often grow to palm-sized proportions, but their naturally occurring ancestors were far smaller ...

In recent years, scientists have created a range of new methods based on CRISPR-Cas technology for precisely editing the ...

But the incumbents look set to fight to hold on to the market, with Alnylam Pharmaceuticals sharing early-phase data on its ...

Phase 1 data indicate Intellia’s medicine could be a powerful treatment for a cardiac form of ATTR amyloidosis. But rival drugs are further ahead.

Analysts appear optimistic for Intellia’s gene editor nex-z, which showed a greater serum TTR reduction than Alnylam’s ...

This study presents important findings on cold tolerance shared between hibernating and non-hibernating mammals, identifying a key molecule, GPX4, through multi-species genome-wide CRISPR screens. The ...

Intellia Therapeutics CEO John Leonard has, for the last couple years, found himself stuck in a financial Groundhog Day.

Try Now>> See Insiders’ Hot Stocks on TipRanks >> Read More on CRSP: CRISPR Therapeutics NewsMORE Related Stocks Indices Commodities Currencies Stocks ...

We recently compiled a list of the ARK Invest Stock Portfolio: Top 10 Stock Picks for 2024. In this article, we are going to ...